These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8387426)

  • 1. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism.
    Tepel M; Husseini S; Zidek W
    Eur J Clin Pharmacol; 1993; 44 Suppl 1():S51-2. PubMed ID: 8387426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of inhibition of Na, K-ATPase on cytosolic free sodium and calcium in platelets of spontaneously hypertensive rats.
    Tepel M; Husseini S; Wischniowski H; Zidek W
    Am J Hypertens; 1992 Oct; 5(10):740-3. PubMed ID: 1329851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
    Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
    Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone prevents Na+/H+ exchange enhancement in primary aldosteronism.
    Koren W; Koldanov R; Postnov IY; Postnov YV
    Am J Hypertens; 1997 Mar; 10(3):341-5. PubMed ID: 9056693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
    Mihailidou AS; Mardini M; Funder JW; Raison M
    Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell membrane cation transport systems during aldosterone antagonism.
    Lijnen P; Petrov V
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):462-8. PubMed ID: 8847860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cytosolic free sodium concentrations in platelets from type 2 (non-insulin-dependent) diabetic patients is associated with hypertension.
    Tepel M; Bauer S; Husseini S; Raffelsiefer A; Zidek W
    J Endocrinol; 1993 Sep; 138(3):565-72. PubMed ID: 8277228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced cytosolic free Na+ concentration in intact platelets of essential hypertensives.
    Tepel M; Bauer S; Husseini S; Zidek W
    J Hypertens; 1992 Sep; 10(9):991-6. PubMed ID: 1328381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
    Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
    Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans.
    Olivieri O; Castagna A; Guarini P; Chiecchi L; Sabaini G; Pizzolo F; Corrocher R; Righetti PG
    Hypertension; 2005 Oct; 46(4):683-8. PubMed ID: 16172430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cytosolic free sodium in platelets from patients with early-stage chronic renal failure.
    Tepel M; Bauer S; Kegel M; Raffelsiefer A; Wischniowski H; Zidek W
    Nephrol Dial Transplant; 1994; 9(1):27-34. PubMed ID: 8177473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma renin activity after administration of spironolactone.
    Maebashi M; Yoshinaga K
    Jpn Circ J; 1967 Mar; 31(3):435-9. PubMed ID: 6072372
    [No Abstract]   [Full Text] [Related]  

  • 14. Endogenous inhibitors of the Na+, K(+)-pump and platelet Ca2+ handling in hypertension.
    Devynck MA; David-Dufilho M; Astarie C; Mazeaud M; Pernollet MG; Le Quan Sang KH
    Physiol Bohemoslov; 1990; 39(1):71-8. PubMed ID: 2165268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.
    Loh KC; Koay ES; Khaw MC; Emmanuel SC; Young WF
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2854-9. PubMed ID: 10946893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular sodium and potassium concentrations in erythrocytes of patients with primary aldosteronism.
    Oshima T; Matsuura H; Matsumoto K; Shingu T; Kajiyama G; Mitsuda H; Ninomiya M
    Jpn J Med; 1988 Aug; 27(3):281-5. PubMed ID: 3193658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Na(+)-H+ exchange in red blood cells of patients with primary aldosteronism.
    Koren W; Postnov IY; Postnov YV
    Hypertension; 1997 Feb; 29(2):587-91. PubMed ID: 9040443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume-pressure relationships during development of mineralocorticoid hypertension in man.
    Wenting GH; Man in 't Veld AJ; Verhoeven RP; Derkx FH; Schalekamp DH
    Circ Res; 1977 May; 40(5 Suppl 1):I163-70. PubMed ID: 858175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump.
    Mihailidou AS; Bundgaard H; Mardini M; Hansen PS; Kjeldsen K; Rasmussen HH
    Circ Res; 2000 Jan 7-21; 86(1):37-42. PubMed ID: 10625303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiopathological and functional semeiologic considerations in a case of primary normoaldosteronemic hyperaldosteronism].
    Bruschi G; Banchini E; Mutti A; Biggi A; Coruzzi P; Civardi E; Martinelli M; Novarini A
    Ateneo Parmense Acta Biomed; 1977; 48(2):157-65. PubMed ID: 883997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.